Breaking News

Tweet TWEET

Anacor Pharmaceuticals Announces That GSK Has Discontinued Clinical Development of GSK2251052

  Anacor Pharmaceuticals Announces That GSK Has Discontinued Clinical
  Development of GSK2251052

Business Wire

PALO ALTO, Calif. -- October 05, 2012

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its collaboration
partner GlaxoSmithKline (GSK) has discontinued clinical development of
GSK2251052. As previously disclosed, GSK halted the most recent clinical
trials of GSK2251052 due to the identification of microbiological findings of
resistance in a small number of patients in the Phase 2b trial for the
treatment of complicated urinary tract infections (cUTI). Since then, GSK has
conducted additional pre-clinical research and, after assessing various
options, has elected to discontinue further development of GSK2251052 and
return all rights to GSK2251052 to Anacor. Anacor and GSK are currently
working together to transition GSK2251052 back to Anacor.

Anacor licensed GSK2251052 to GSK in July 2010 under the companies' ongoing
research and development collaboration. GSK is continuing to fund Anacor’s
research activities in tuberculosis as announced in September 2011 under the
companies’ amended R&D collaboration.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor has discovered six compounds that are currently in
development. Its two lead product candidates are topically administered
dermatologic compounds - tavaborole, a topical antifungal for the treatment of
onychomycosis and AN2728, a topical anti-inflammatory PDE-4 inhibitor for the
treatment of atopic dermatitis and psoriasis. In addition to its two lead
programs, Anacor has discovered two other clinical product candidates, AN2718
and AN2898, which are backup compounds to tavaborole and AN2728, respectively.
The Company has also discovered two compounds that it has out-licensed for
further development - AN8194, which is licensed to Eli Lilly and Company for
an animal health indication and AN5568, which is licensed to the Drugs for
Neglected Diseases initiative for sleeping sickness. In addition, Anacor has a
research and development agreement with Medicis Pharmaceuticals to discover
and develop boron-based small molecule compounds directed against a target for
the potential treatment of acne. For more information, visit
http://www.anacor.com.

Forward-Looking Statements

This press release may contain forward-looking statements that relate to
future events including the potential future development or licensing of
GSK2251052 once returned to Anacor. These forward looking statements involve
known and unknown risks, uncertainties and other factors that could cause
actual events to differ materially from those expressed or implied by these
forward-looking statements. These statements reflect the views of Anacor as of
the date of this press release with respect to future events and, except as
required by law, it undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information, future
events or otherwise after the date of this press release.

Contact:

Anacor Pharmaceuticals
DeDe Sheel, 650-543-7575
Investor Relations and Corporate Communications
dsheel@anacor.com
 
Press spacebar to pause and continue. Press esc to stop.